Epithalon

What is Epithalon?

Epithalon (also written Epitalon, and known as the AEDG peptide) is a synthetic four-amino-acid peptide with the sequence Alanine-Glutamate-Aspartate-Glycine. It was designed in Russia as a short, stable analog of Epithalamin, a polypeptide extract of the pineal gland studied there for several decades.

It is investigated as a longevity or "anti-aging" peptide, with proposed effects on the enzyme telomerase and on the pineal gland's regulation of melatonin and circadian rhythm. Epithalon is not an FDA-approved drug; in the United States it is available only as a pharmacy-compounded preparation prescribed under physician supervision, and its evidence base is preliminary rather than settled.

How Epithalon works

The most-discussed proposed mechanism is activation of telomerase, the enzyme that adds DNA to the protective telomere caps on chromosomes. In cell-culture work, Epithalon has been reported to induce telomerase expression and lengthen telomeres in human somatic cells, which is the basis for the cellular-aging hypothesis around the peptide.

Its second proposed action is on the pineal axis: as a fragment related to pineal peptides, Epithalon is theorized to help normalize melatonin secretion and circadian rhythm, along with effects on antioxidant and neuroendocrine signaling. These mechanisms are drawn largely from laboratory and animal models, and how well they translate to meaningful outcomes in healthy people is not established.

What Epithalon is used for

What the evidence shows

Most Epithalon research originates from a single group of investigators in Russia and appears in that country's literature, spanning cell-culture, animal, and some human studies. Laboratory work reports telomerase induction and telomere lengthening in human cell lines, and rodent studies have described effects on lifespan and tumor incidence [1][2].

A frequently cited long-term human observation reported reduced mortality over several years of follow-up in older patients given the pineal peptide preparation [3]. These findings are genuinely interesting, but they come with important caveats: much of the work is decades old, has not been widely replicated by independent groups outside Russia, and the modern human data are limited in size and rigor.

We present this candidly to every patient. Epithalon sits in the category of a preliminary compound with a plausible mechanism and suggestive early data — not one supported by large, replicated randomized trials. That distinction matters when you are deciding whether it fits your goals.

Dosing & administration context

In the published protocols and clinical use, Epithalon is most often given as a short course of subcutaneous injections, sometimes repeated once or twice a year, with the dose expressed in milligrams per course. Some studies used intranasal or intramuscular routes of the parent pineal preparation.

The specific dose, route, frequency, and duration are individualized by the prescribing physician — which is why we frame this as clinical context, not a self-dosing guide. Epithalon obtained without a prescription (research-only vials, gray-market powders) carries no guarantee of identity, purity, or sterility, and the peptide is a common target for counterfeit product.

Epithalon is not an FDA-approved medication. Content on this page is clinical context for physician-supervised, pharmacy-compounded use — not a dosing guide or a substitute for medical advice. The evidence base is preliminary and not widely replicated.

Safety & side effects

In the reported studies and in clinical use, Epithalon has generally been described as well tolerated, with no consistent pattern of serious toxicity at the doses used. Reported effects are typically mild and self-limiting.

Because the human safety database is small and comes largely from one research tradition, we screen carefully before prescribing and monitor throughout a course. As with any peptide, the most important safety principle is source control — a pharmacy-compounded product from a licensed 503A/503B pharmacy is a fundamentally different risk profile than a research vial of unknown origin. Telomerase activation is also a theoretical concern in the setting of active cancer.

How Strong Health prescribes Epithalon

At Strong Health, Epithalon is prescribed only after a physician evaluation and a candid conversation about what the evidence does and does not show. It is dispensed exclusively through licensed 503A or 503B compounding pharmacies under physician orders; we do not sell or recommend research-only product.

We treat Epithalon as an optional, elective component of a longevity plan rather than a proven therapy, and we set expectations accordingly. Your physician sets the protocol, screens for contraindications such as active cancer, reviews your response at scheduled intervals, and adjusts or stops treatment based on how you actually do.

Available in person at our Miami (Brickell) clinic and via telehealth across our service areas.

Frequently asked questions